Alzheimer's Boom or Bust Podcast Por  arte de portada

Alzheimer's Boom or Bust

Alzheimer's Boom or Bust

Escúchala gratis

Ver detalles del espectáculo

Aducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode are joined by P4 student Ise Brockmann to dive into aducanumab's story.

email: econrxpodcast@gmail.com

Twitter/Instagram: @EconRx

LinkedIn: www.linkedin.com/company/econrx

Website: https://econrx.libsyn.com/

Todavía no hay opiniones